Ebglyss (Lebrikizumab-lbkz) for Eczema

Overview
Ebglyss is approved by the U.S. Food and Drug Administration (FDA) to treat moderate-to-severe atopic dermatitis (the most common form of eczema) in adults and children 12 years and older. It is prescribed when eczema is not adequately controlled by topical prescription treatments or when those treatments are not advisable. Ebglyss can be used alone or in combination with topical corticosteroids. Ebglyss is also known by its drug name, lebrikizumab-lbkz.

Ebglyss belongs to a class of drugs called interleukin (IL)-13 antagonists. It works by blocking the activity of IL-13, a protein that contributes to the inflammation and itching characteristic of eczema. By reducing IL-13 activity, Ebglyss helps manage symptoms like redness, itching, and skin damage associated with eczema.

How do I take it?
Prescribing information states that Ebglyss is administered as a subcutaneous (under the skin) injection. The starting dosage is given at Week 0 and Week 2. After that, an injection is given every two weeks until Week 16 or later, once an adequate clinical response is achieved. The maintenance dosing schedule is one injection every four weeks. The drug should be administered exactly as prescribed by a health care provider.

Side effects
Common side effects of Ebglyss include conjunctivitis (eye inflammation), injection site reactions, and herpes zoster (shingles).

Rare but serious side effects may include hypersensitivity reactions (such as angioedema and urticaria), new or worsening eye problems (such as conjunctivitis and keratitis), and parasitic infections (helminth infections) that may require stopping treatment if they do not respond to anti-parasitic medications. Additionally, people taking Ebglyss should avoid receiving live vaccinations.

For more information about this treatment, visit:

Ebglyss (Lebrikizumab-Lbkz), Injection, for Subcutaneous Use — U.S. Food & Drug Administration

Ebglyss — Drugs.com